| Extended indication |
Treatment of patients with relapsed or refractory non-APL AML (acute promyelocytenleukemie is een subtype van acute myeloïde leukemie), relapsed or refractory higher-risk MDS (myelodysplastic syndrome), newly diagnosed treatment naïve AML, or transfusion dependent, lower-risk MDS.
|